Paul Hastings LLP has extensive expertise in IPOs for common stock shares, acting on behalf of issuers and underwriters mainly focused on the oil and gas, chemicals energy transition, and infrastructure spheres. The team routinely represents investment banks, public companies, and venture capital funds, with New York-based Frank Lopez heading the firm’s global securities and capital markets practice. Also operating out of New York, Colin Diamond has vast knowledge in registered equity offerings, private placements, and convertible bond offerings, with Seo Salimi standing out for his. work in cross-border capital market transactions in the life sciences field.
Legal 500 Editorial commentary
- Profile
Key clients
- Goldman Sachs
- J.P. Morgan Securities
- Morgan Stanley
- Jefferies
- Barclays
- BofA Securities
- Piper Sandler and Co.
- TD Securities (USA) LLC
- Guggenheim Securities Inc.
- Leerink Partners, LLC
Work highlights
- Represented Viking Therapeutics, Inc., as issuer, in its USD $632.5 million follow-on public offering of its common stock.
- Represented Kyverna Therapeutics, Inc., as issuer, in its upsized initial USD $366.9 million public offering.
- Advised Goldman Sachs & Co. LLC, J.P. Morgan, TD Cowen, and Stifel as joint bookrunning managers in connection with Syndax Pharmaceuticals’ USD $230 million public offering.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Frank Lopez; Colin Diamond; Eric Sibbitt; Jeff Hartlin; Seo Salimi; David Ambler